Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN-2409 in Active Surveillance for Localized Prostate Cancer
NCT02768363Phase 2Active, not recruiting
- Sponsor
- Candel Therapeutics
- Start
- May 2016
- Primary completion
- Nov 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
A Phase 2 trial of aglatimagene besadenovec in prostate cancer (PCa), sponsored by Candel Therapeutics. Started May 2016; status: active, not recruiting.
02
Drugs
aglatimagene besadenovec
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02768363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02768363.